Cargando…
Updates on Pharmacologic Management of Microvascular Angina
Microvascular angina (MVA), historically called cardiac syndrome X, refers to angina with nonobstructive coronary artery disease. This female-predominant cardiovascular disorder adds considerable health-related costs due to repeated diagnostic angiography and frequent hospital admissions. Despite th...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9626221/ https://www.ncbi.nlm.nih.gov/pubmed/36382021 http://dx.doi.org/10.1155/2022/6080258 |
_version_ | 1784822688996392960 |
---|---|
author | Soleymani, Mosayeb Masoudkabir, Farzad Shabani, Mahsima Vasheghani-Farahani, Ali Behnoush, Amir Hossein Khalaji, Amirmohammad |
author_facet | Soleymani, Mosayeb Masoudkabir, Farzad Shabani, Mahsima Vasheghani-Farahani, Ali Behnoush, Amir Hossein Khalaji, Amirmohammad |
author_sort | Soleymani, Mosayeb |
collection | PubMed |
description | Microvascular angina (MVA), historically called cardiac syndrome X, refers to angina with nonobstructive coronary artery disease. This female-predominant cardiovascular disorder adds considerable health-related costs due to repeated diagnostic angiography and frequent hospital admissions. Despite the high prevalence of this diagnosis in patients undergoing coronary angiography, it is still a therapeutic challenge for cardiologists. Unlike obstructive coronary artery disease, with multiple evidence-based therapies and management guidelines, little is known regarding the management of MVA. During the last decade, many therapeutic interventions have been suggested for the treatment of MVA. However, there is a lack of summarization tab and update of current knowledge about pharmacologic management of MVA, mostly due to unclear pathophysiology. In this article, we have reviewed the underlying mechanisms of MVA and the outcomes of various medications in patients with this disease. Contrary to vasospastic angina in which normal angiogram is observed as well, nitrates are not effective in the treatment of MVA. Beta-blockers and calcium channel blockers have the strongest evidence of improving the symptoms. Moreover, the use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, statins, estrogen, and novel antianginal drugs has had promising outcomes. Investigations are still ongoing for vitamin D, omega-3, incretins, and n-acetyl cysteine, which have resulted in beneficial initial outcomes. We believe that the employment of the available results and results of the future large-scale trials into cardiac care guidelines would help reduce the global cost of cardiac care tremendously. |
format | Online Article Text |
id | pubmed-9626221 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-96262212022-11-14 Updates on Pharmacologic Management of Microvascular Angina Soleymani, Mosayeb Masoudkabir, Farzad Shabani, Mahsima Vasheghani-Farahani, Ali Behnoush, Amir Hossein Khalaji, Amirmohammad Cardiovasc Ther Review Article Microvascular angina (MVA), historically called cardiac syndrome X, refers to angina with nonobstructive coronary artery disease. This female-predominant cardiovascular disorder adds considerable health-related costs due to repeated diagnostic angiography and frequent hospital admissions. Despite the high prevalence of this diagnosis in patients undergoing coronary angiography, it is still a therapeutic challenge for cardiologists. Unlike obstructive coronary artery disease, with multiple evidence-based therapies and management guidelines, little is known regarding the management of MVA. During the last decade, many therapeutic interventions have been suggested for the treatment of MVA. However, there is a lack of summarization tab and update of current knowledge about pharmacologic management of MVA, mostly due to unclear pathophysiology. In this article, we have reviewed the underlying mechanisms of MVA and the outcomes of various medications in patients with this disease. Contrary to vasospastic angina in which normal angiogram is observed as well, nitrates are not effective in the treatment of MVA. Beta-blockers and calcium channel blockers have the strongest evidence of improving the symptoms. Moreover, the use of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, statins, estrogen, and novel antianginal drugs has had promising outcomes. Investigations are still ongoing for vitamin D, omega-3, incretins, and n-acetyl cysteine, which have resulted in beneficial initial outcomes. We believe that the employment of the available results and results of the future large-scale trials into cardiac care guidelines would help reduce the global cost of cardiac care tremendously. Hindawi 2022-10-25 /pmc/articles/PMC9626221/ /pubmed/36382021 http://dx.doi.org/10.1155/2022/6080258 Text en Copyright © 2022 Mosayeb Soleymani et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Soleymani, Mosayeb Masoudkabir, Farzad Shabani, Mahsima Vasheghani-Farahani, Ali Behnoush, Amir Hossein Khalaji, Amirmohammad Updates on Pharmacologic Management of Microvascular Angina |
title | Updates on Pharmacologic Management of Microvascular Angina |
title_full | Updates on Pharmacologic Management of Microvascular Angina |
title_fullStr | Updates on Pharmacologic Management of Microvascular Angina |
title_full_unstemmed | Updates on Pharmacologic Management of Microvascular Angina |
title_short | Updates on Pharmacologic Management of Microvascular Angina |
title_sort | updates on pharmacologic management of microvascular angina |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9626221/ https://www.ncbi.nlm.nih.gov/pubmed/36382021 http://dx.doi.org/10.1155/2022/6080258 |
work_keys_str_mv | AT soleymanimosayeb updatesonpharmacologicmanagementofmicrovascularangina AT masoudkabirfarzad updatesonpharmacologicmanagementofmicrovascularangina AT shabanimahsima updatesonpharmacologicmanagementofmicrovascularangina AT vasheghanifarahaniali updatesonpharmacologicmanagementofmicrovascularangina AT behnoushamirhossein updatesonpharmacologicmanagementofmicrovascularangina AT khalajiamirmohammad updatesonpharmacologicmanagementofmicrovascularangina |